Arnatar Therapeutics
Recent Finacing
Series A
Recent Raise
$52M
Arnatar develops RNA therapeutics with ACT‑UP1 and DARGER (siRNA plus upregulating ASOs); lead ART4 upregulates JAG1 with monthly subcutaneous dosing and targets cardiometabolic, liver, CNS, kidney diseases.
Highlights
Focus Areas
Biopharma
Medical
Recent Investors
Financials
$52M
Total Raised
1
Funding round
11
Investors